E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10044552 |
E.1.2 | Term | Traveller's diarrhea |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to evaluate the efficacy of the TD Vaccine System to prevent moderate to severe ETEC disease in a field setting. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives of the study are to evaluate the efficacy of the TD Vaccine System to alleviate symptoms and characteristics associated with TD and to reduce the burden of gastrointestinal (GI) illness experienced, as well as to evaluate the safety and immunogenicity of the vaccine. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
A subject may be included in the study if he/she meets all of the following inclusion criteria: 1. 18-64 years of age at date of first vaccination 2. Good health as determined by medical history and physical inspection 3. Females of child-bearing potential must have a negative pregnancy test prior to first and second vaccination in the country of origin; females of childbearing potential must agree not to become pregnant throughout the duration of study 4. Subjects must have planned travel to an area within 3 hours traveling distance of Mexico City, Cuernavaca, Guadalajara, Oaxaca, or San Miguel de Allende, Mexico or Antigua, Quetzaltenango, Guatemala City, or Solola, Guatemala for a minimum duration of stay of 7 days (no maximum stay is specified for inclusion) 5. Subject must be able to communicate in English
|
|
E.4 | Principal exclusion criteria |
A subject meeting any of the following criteria during the screening period is not eligible for participation in the study: 1. Abnormalities as determined by the Investigator/clinician during physical inspection; 2. Participated in research involving investigational product within 30 days before planned date of first vaccination; 3. Ever received LT, ETEC, or cholera vaccine; 4. History of diarrhea while traveling in a developing country within the last year; 5. Women who are pregnant or breastfeeding; 6. Clinically significant underlying enteric, pulmonary, cardiac, liver or renal disease; 7. History of Irritable Bowel Syndrome; 8. Seizure disorder within the last year; 9. Current use of immunosuppressive therapy (excluding inhaled steroids) or immunodeficiency; 10. Known or suspected alcohol abuse or illicit drug use within the last year; 11. Medical history of HIV, HBV, or HCV; 12. An employee of a study site; 13. Known allergies to any component of the vaccine, including adhesives; 14. Planned use of antibiotics with known activity against gram negative facultative anaerobes; 15. Planned use of antacids, antidiarrheals, loperamide, bismuth subsalicylate, diphenoxylate or similar from two weeks prior to randomization through the surveillance phase of the study. 16. An employee of Intercell (global) or an immediate family member.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• The incidence of cases with vaccine preventable outcome (VPO) reported during the surveillance period; VPO is all moderate/severe diarrheal cases in which LT, LT/ST or ST toxins (ETEC) are detected by either PCR or DNA hybridization (and no co-pathogen is detected) from diarrheal stool samples that are collected during the first diarrheal episode
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Administration to healthy volunteers |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
As provided in the protocol. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |